Minerva price target raised to $5 from $3 at Jefferies

Jefferies raised the firm’s price target on Minerva (NERV) to $5 from $3 and keeps a Hold rating on the shares. Oral roluperidone has the potential to benefit the negative symptoms of schizophrenia, an indication with no approved therapies, the analyst tells investors in a research note, adding that management has aligned with the FDA to initiate a confirmatory Phase III trial in 2026. The firm also said that, ultimately, it expects Minerva stock to climb on decreased time value to the Phase III dataset in 2028.